Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible relationship between both disorders was discussed.

Primary pulmonary Hodgkin lymphoma (PPHL) is very rare and typically involves the superior portion of the lung. Pulmonary involvement is observed in 15-40% of Hodgkin lymphoma patients. Three such patients who presented with an unusual form of PPHL in radiological studies, i.e., multiloculated cavitary lesions, were admitted to our hospital. These lesions represent a new pathological and radiol...

Non-Hodgkin lymphoma can occur concurrently with chronic phase-chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second-generation tyrosine kinase inhibitors and rituximab-CHOP for patients newly diagnosed with CML and non-Hodgkin lymphoma is effective for both diseases. However, we found that this treatment combination may induce severe myelosuppression.

BACKGROUND Persons infected with human immunodeficiency virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear. METHODS Patient records were linked between the Swiss HIV Cohort Study and Swiss cantonal cancer registries. Observ...

Non–Hodgkin lymphoma (NHL) causes many deaths worldwide with increasing incidence. Non-Hodgkin's lymphoma (NHL) may involve the gynecologic tract, and the ovary to be one of the commoner anatomic sites as reported. Ovarian involvement by NHL is usually secondary, occurring as a part of systemic disease. The diagnosis is often made incidentally while investigating for gynecological symptoms. We ...

PURPOSE Galectin-1 (Gal1) is an immunomodulatory glycan-binding protein regulated by an AP1-dependent enhancer in Hodgkin Reed-Sternberg cells. We recently found that Reed-Sternberg cell Gal1 promotes the immunosuppressive T-helper 2/T-regulatory cell-skewed microenvironment in classical Hodgkin lymphoma (cHL). We sought to investigate whether the coordinate expression of activated AP1 pathway ...

Over the past 30 years, the survival rate of patients with non-Hodgkin lymphoma and Hodgkin lymphoma has significantly improved. In the mid 1970s, patients with non-Hodgkin lymphoma were expected to have a 5-year survival of approximately 45%. In 2008, it is estimated that 60–70% of patients with non-Hodgkin lymphoma would be alive after 5 years from diagnoses. The improvement in patient’s surv...

INTRODUCTION Hodgkin Lymphoma (HL) is a group of lymphomas of mainly nodal origin with similar clinical and histological features (1). HL encompasses 95% of classical Hodgkin lymphomas (CHL) and the rest are of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). These two entities differ in their aetiology, clinical features, histopathological features, immunophenotype and molecular geneti...

Lymphoma is a malignant neoplasm of lymphoid tissue which is divided into 2 groups: Hodgkin and non-Hodgkin. About 85% of non-Hodgkin lymphomas are B-cell lymphomas, and T-cell lymphomas are unusual. Anaplastic large cell lymphoma (ALCL) is a kind of non-Hodgkin lymphoma with T or NK cell origin that is rarely seen in the oral cavity and only 10 cases have been reported up to now. Here we prese...

In the present study, we report on the full range of physical diseases acquired by survivors of Hodgkin lymphoma diagnosed in adolescence or young adulthood. In a Danish nationwide population-based cohort study, 1,768 five-year survivors of Hodgkin lymphoma diagnosed at ages 15-39 years during 1943-2004 and 228,447 comparison subjects matched to survivors on age and year of birth were included....